Abeona Therapeutics (NASDAQ: ABEO) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Abeona Therapeutics to similar businesses based on the strength of its risk, valuation, institutional ownership, profitability, earnings, dividends and analyst recommendations.
Earnings & Valuation
This table compares Abeona Therapeutics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Abeona Therapeutics||$842,999.00||-$23.80 million||-31.72|
|Abeona Therapeutics Competitors||$207.83 million||-$2.34 million||0.16|
This table compares Abeona Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Abeona Therapeutics Competitors||-3,989.23%||-119.42%||-44.20%|
This is a breakdown of recent ratings and recommmendations for Abeona Therapeutics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Abeona Therapeutics Competitors||468||2234||6126||117||2.66|
Abeona Therapeutics currently has a consensus target price of $22.88, suggesting a potential upside of 18.22%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.57%. Given Abeona Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Abeona Therapeutics is more favorable than its peers.
Insider & Institutional Ownership
38.4% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 6.8% of Abeona Therapeutics shares are owned by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Abeona Therapeutics has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Abeona Therapeutics’ peers have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.
Abeona Therapeutics beats its peers on 7 of the 12 factors compared.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
What are top analysts saying about Abeona Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abeona Therapeutics Inc. and related companies.